Waters Corporation Hits the Ground Running on BD Integration, Raises Full-Year Outlook After Blowout First Quarter
Q1 2026 Earnings Call, May 5, 2026 — First Quarter as a Combined Company with Becton Dickinson Biosciences and Diagnostic Solutions
Waters Corporation delivered a first quarter that materially exceeded expectations on nearly every line, and did so less than 90 days after closing its transformative acquisition of the Biosciences and Diagnostic Solutions businesses from Becton Dickinson on February 9. The company beat its own organic revenue guidance by 200 basis points, generated a $40 million revenue beat on the newly acquired BD assets, and grew adjusted EPS 20% year-over-year to $2.70, $0.35 above the top of its guidance range. The strong print prompted a raise in full-year organic growth guidance and an upward revision to EPS, though the magnitude of the EPS raise — just $0.10 — was deliberately conservative, with management embedding incremental caution into the second-half outlook.
The BD Acquisition: Better Than Feared From Day One
The central question heading into this call was whether Waters could stabilize the BD businesses, which had been deteriorating before the deal closed, and the answer from the first owned period is unambiguously yes — though with important caveats on China and respiratory headwinds. Total acquired revenue for the period of ownership came in at $520 million, $40 million above guidance, representing an estimated 7% as-reported growth versus the comparable prior-year stub period. On a full-quarter pro forma basis, which is the more meaningful comparator, the acquired businesses grew flat year-over-year — a stark improvement from the double-digit declines registered in the fourth quarter of 2025 under BD's management. Excluding roughly $20 million of respiratory testing headwind tied to a weak flu season, pro forma growth was approximately 3% for the full quarter.
CEO Udit Batra was candid that much of this improvement reflects execution discipline rather than market tailwinds. Within 90 days of closing, Waters deployed what it calls a "180-day plan" centered on three priorities: installing forecast rigor and accountability, implementing pricing discipline, and localizing the Chinese product portfolio. The early impact has been tangible. Weekly customer call rates in the U.S. Advanced Diagnostics business have roughly doubled. Two new deal desks have been stood up across Biosciences and Diagnostic Solutions. A review of approximately 1,600 U.S. Diagnostic Solutions reagent rental contracts found that nearly 700, or close to half, are out of compliance, representing what management described as a "double-digit million dollar shortfall annually." None of these pricing and compliance recovery opportunities are embedded in the current guidance, meaning they represent potential upside as remediation progresses through the year.
Microbiology: The Clearest Turnaround Signal
Of the two acquired divisions, Diagnostic Solutions showed the more dramatic inflection. The Diagnostic Solutions business grew 1% on a full-quarter pro forma basis, up from a high single-digit decline in Q4 2025. Microbiology, the largest piece at $203 million, grew 5% for the full quarter, with ex-China growth running at high single digits. Batra tied this directly to the installation of KPI discipline ahead of the BACTEC FXI launch. "Microbiology has the same characteristics, high-volume regulated applications with significant unmet needs," he said, drawing an explicit parallel to the legacy Waters Analytical Sciences business, which has compounded above-market for years using exactly this playbook.
The BACTEC FXI blood culture system received CE marking under the EU's in vitro diagnostic regulation ahead of schedule and is now available in Europe and Japan, with additional regulatory approvals pursued globally. Management described it as combining industry-leading automation, 60-sample loading capacity, and a detection time three hours faster than the current-generation BACTEC system, which is over a decade old. Of the 22,000 instruments across the acquired installed base ripe for replacement, 12,000 are BACTEC units, with over half more than five years old and over a quarter more than ten years old. Waters has already pulled forward the U.S. and European BACTEC FXI launch by three to five months relative to the inherited business case, accelerating what is a large and visible revenue synergy opportunity.
Biosciences: China Remains the Drag, but Localization Is Underway
The Biosciences Division, comprising the former BD Biosciences flow cytometry business, delivered $232 million for the owned period, representing 7% estimated as-reported growth, with both Flow Research and Flow Clinical each growing 7%. Reagents grew low double digits. Instruments, however, remained under pressure from two distinct headwinds: U.S. academic and government spending weakness — a sector-wide issue — and China-specific constraints stemming from export restrictions on high-parameter products and the absence of a localized product portfolio. On a full-quarter pro forma basis, Biosciences declined 1%, though this was a meaningful improvement from the 10% decline in Q4 2025. Ex-China, the business grew 4% for the full quarter.
Waters has approved and initiated China manufacturing localization for flow instruments, with production of key products for the China market expected to begin in the third quarter. Batra noted that this announcement alone is already generating commercial activity, as local manufacturing is a prerequisite for many Chinese government tenders. He drew a direct line to the Analytical Sciences playbook in China, where localization drove over 50% pharma revenue growth in Q1 driven by CDMOs, biotech and emerging innovative domestic pharma companies. On the export control front, Waters has streamlined the compliance process, and management claimed the highest-ever volume of export-controlled orders in the days immediately following the process improvements — though the structural restriction on high-parameter products to China remains an overhang.
Legacy Waters: Replacement Cycle Intact, Chemistry Rerated Higher
The Analytical Sciences Division — the legacy Waters business excluding the Clinical Business Unit — grew 12% in constant currency, with instruments up 8%, chemistry up 13% and service up 14%. Pharma grew 14%, with over 50% growth in China, low-teens in India and high single-digit growth in both the Americas and Europe. Academic and government grew 18%, driven by European budget strength and adoption of the Xevo MRT and Xevo CDMS high-resolution mass spectrometry platforms. Industrial grew low single digits, a soft but expected result given the macro backdrop, with PFAS testing providing a specific growth driver in Europe and China despite a tough prior-year comparison.
The chemistry business has emerged as a standout, prompting a notable guidance rerate. Batra attributed the sustained double-digit growth to a multi-year strategic decision to allocate 70% to 80% of R&D dollars to bioseparations, generating a pipeline of new products — most recently the next-generation Microflow LC Chemistry Columns with MaxPeak Premier technology — that have become the first point of evaluation for virtually all new biologic drug candidates. "There is no reason to believe that all of this will not flow downstream," Batra said, adding that chemistry "should now be instead of a 7% grower, a 9% to 10% grower at least" on a mid- to long-term basis. For the full year, CFO Amol Chaubal guided chemistry at approximately 6.5%, which he acknowledged is deliberately conservative given the strong baseline and pull-forward dynamics flagged in Q2 2025.
CFO Amol Chaubal clarified that approximately four extra working days in Q1 contributed roughly 2 percentage points to organic reported growth via recurring revenue streams, meaning chemistry at 13% and service at 14% are running well above trend even on an adjusted basis. On the replacement cycle, Chaubal sees continued runway into 2027 as CROs, Chinese branded generics and certain biotech segments have yet to refresh significantly overaged fleets. He also outlined a natural bridge from the current replacement cycle into 2028-2029, where reshoring-driven instrument placements are expected to fill what might otherwise be an air pocket as the current cycle matures.
Revenue Synergies: Already Ahead of Plan on Cross-Selling
Waters raised its full-year organic constant currency revenue growth guidance to 6.5% to 8%, up from its prior range, embedding $15 million of revenue synergies from cross-selling of tandem quadrupole mass spectrometry through the Biosciences channel into pharma clinical settings. In Q1, this cross-divisional channel contribution added approximately 1 percentage point to Analytical Sciences growth. Total revenue synergy guidance for 2026 sits at $50 million, with the remaining $35 million assigned to the Biosciences and Diagnostic Solutions businesses and tied to instrument replacement, service plan attachment and e-commerce. The service plan attachment opportunity alone — based on the first-ever full coverage analysis of the flow, microbiology and molecular diagnostics installed bases — is expected to drive at least $20 million of incremental revenue over five years, with account-level KPI assignments beginning this quarter.
The $50 million revenue synergy total does not include the upside from the 180-day plan execution improvements, reagent rental contract compliance recovery, or pricing normalization in the acquired businesses. Management has been consistent in keeping these out of guidance, framing them as potential outperformance vectors rather than baseline assumptions.
Financials: Margins and EPS Constrained Near Term, Recovery Back-Half Loaded
Total company adjusted gross margin was 54.7%, approximately 200 basis points better than expected, and adjusted operating margin was 23.6%, also around 200 basis points above guidance. The strong Q1 margin performance arrived before cost synergies begin to flow through the P&L, which management expects to start in Q3 as restructuring actions currently in advanced implementation take hold. The full-year cost synergy target of $55 million remains intact, driven by organizational de-layering, procurement savings and network optimization.
Full-year adjusted EPS guidance was raised by $0.10 to a range of $14.40 to $14.60, implying 10% to 11% growth — a modest raise relative to the magnitude of Q1 outperformance. Chaubal attributed this conservatism to the full burden of higher interest expense ($186 million net for the full year), the dilutive effect of newly issued shares, a prudent second-half organic growth assumption of approximately 6% constant currency versus Q1's 11%, and the back-half timing of cost synergy realization. Second-quarter adjusted EPS guidance of $2.95 to $3.05 implies flat to low-single-digit growth, as Q2 carries the full interest and share count burden without yet benefiting from synergy savings. On a GAAP basis, Waters reported a diluted loss per share of $0.87 in Q1, driven by acquisition-related purchase accounting charges including amortization of acquired intangibles and inventory step-up. Free cash flow was a $42 million outlay, impacted by deal transaction costs and net cash settlement timing with BD.
New Product Momentum and the BD Onclarity HPV Self-Collection Kit
Beyond the BD legacy turnaround, Waters highlighted two meaningful product clearances in Q1. The BD Onclarity HPV self-collection kit received FDA clearance, enabling at-home cervical cancer screening with extended genotyping for multiple high-risk HPV strains. Management emphasized that nearly one in four U.S. women is not current with cervical cancer screening and that the self-collection format directly addresses access, comfort and avoidance barriers. Waters has begun signing contracts with strategic distribution partners. Additionally, the omniDAWN multi-angle light scattering detector — described as an industry-first extended-range detector for use in UPLC — was launched within the light scattering franchise, targeting rising throughput and resolution requirements in large-molecule applications.
Guidance and the Multi-Phase Value Creation Framework
Total 2026 reported revenue guidance was set at approximately $6.405 billion to $6.455 billion, with the acquired Biosciences and Diagnostic Solutions businesses expected to contribute approximately $3.035 billion and the organic legacy business contributing $3.37 billion to $3.42 billion. Full-year adjusted EBIT margin is guided at 28.2%, with solid margin progression expected in the second half as cost actions, synergy savings and operating leverage combine. Management committed to at least 100 basis points of adjusted operating margin expansion annually through the end of the decade and framed a mid-teens adjusted EPS growth algorithm as the steady-state target of the combined company.
Batra characterized the path forward in three phases: Phase 1, currently underway, is operational improvement and early cross-selling; Phase 2, beginning in Q3, adds the first tranche of formal revenue synergy levers; Phase 3 is the strategic combination fully expressed through new platform launches such as rapid sterility testing and bioseparations applications in QC and bioanalytical characterization. The trajectory, he argued, mirrors the transformation of the legacy Waters business over the prior five years — a credible analogy if execution holds, and one the market will now be watching closely quarter by quarter.
Waters Corporation Deep Dive
Business Model and Core Operations
Waters Corporation operates as a premier designer and manufacturer of precision analytical instruments, specializing in High-Performance Liquid Chromatography, Mass Spectrometry, and thermal analysis. Historically, the company has operated on a classic razor-and-blade business model. It sells high-margin, capital-intensive scientific instruments to laboratory customers, which subsequently lock those customers into a lucrative stream of recurring revenues derived from precision chemistry consumables, service contracts, and proprietary informatics licenses. The company's Empower Chromatography Data System serves as the central nervous system for regulated laboratories, deeply entrenching Waters into the daily operational workflows of its customer base and ensuring strict compliance with global regulatory standards.
The company recently underwent the most profound structural transformation in its corporate history. In early 2026, Waters completed a $17.5 billion Reverse Morris Trust transaction to acquire the Biosciences and Diagnostic Solutions division of Becton Dickinson. This combination radically altered the financial and operational profile of the company, doubling its total addressable market to approximately $40 billion and establishing a pro forma enterprise generating roughly $6.5 billion in annual revenue. More importantly, this acquisition fundamentally shifted the company's revenue mix, driving annual recurring revenues to over 70 percent by integrating high-volume clinical diagnostics, flow cytometry, and microbiology testing platforms into the legacy analytical instrumentation portfolio. Following this transaction, Waters reorganized into four distinct operating divisions: Analytical Sciences, Biosciences, Advanced Diagnostics, and Materials Sciences.
Ecosystem Dynamics: Customers and Competition
Prior to the transformational diagnostics acquisition, Waters derived more than 60 percent of its revenues from the pharmaceutical and biotechnology end markets. These customers utilize Waters' systems across the entire drug development lifecycle, from early-stage molecular discovery to late-stage quality assurance and manufacturing quality control. The remainder of the legacy customer base spans the industrial, materials, and applied markets, including food safety and environmental testing. The recent integration of the Becton Dickinson assets significantly expands the company's reach into the clinical diagnostics and hospital laboratory ecosystems. In these high-throughput environments, the end customers prioritize absolute reliability, automation, and rapid turnaround times to inform critical patient care decisions, representing a distinct operational cadence compared to traditional pharmaceutical research laboratories.
The competitive landscape for analytical instrumentation and life science tools is characterized by high barriers to entry and intense technological rivalry. Waters' traditional peer group includes Agilent Technologies, Thermo Fisher Scientific, Danaher's SCIEX division, Shimadzu Corporation, and Bruker. Agilent remains the most direct competitor in the liquid chromatography and gas chromatography segments, while Thermo Fisher Scientific is the dominant incumbent in the global mass spectrometry arena. In the newly entered clinical diagnostics and flow cytometry markets, Waters now directly competes with entrenched medical technology conglomerates such as Roche. Despite the fragmented nature of the broader tools market, Waters differentiates itself by providing an unbroken analytical chain, linking precision hardware with ubiquitous compliance software.
On the supply side, the production of high-performance analytical equipment requires extreme precision engineering. Waters maintains a highly vertically integrated manufacturing strategy to protect its intellectual property and ensure the exacting tolerances required by its instruments. For instance, the company machines the specialized components for its MaxPeak Premier chromatography columns at its dedicated facilities in Massachusetts. This vertical integration insulates the company from severe supply chain shocks, ensures rigorous quality control, and sustains the elevated gross margins typical of premium scientific instrumentation.
Market Share and Structural Moats
Waters holds an undisputed leadership position in the global High-Performance Liquid Chromatography market, commanding an estimated 40 percent global revenue share. This dominance is anchored by flagship platforms such as the ACQUITY and Alliance systems, which serve as the industry benchmarks for separation science. In the mass spectrometry market, Waters firmly occupies the number-two position globally, trailing only Thermo Fisher Scientific. The mass spectrometry sector exhibits moderate consolidation, with the top five vendors controlling roughly 60 percent of the global revenue base. This concentration reflects the immense capital requirements and specialized intellectual property necessary to engineer high-resolution ion mobility and time-of-flight spectrometers.
The most formidable competitive advantage protecting Waters' market share is its Empower software franchise. Empower is utilized in over 80 percent of all novel drug submissions to regulatory authorities worldwide. This software establishes an almost insurmountable structural moat built on switching costs. Once a pharmaceutical quality control laboratory integrates Empower, validates its analytical methods, and trains its workforce on the interface, displacing the system becomes economically and operationally prohibitive. Ripping out a validated software platform requires massive capital outlay, extensive retraining, and the agonizing process of re-validating testing protocols with regulatory agencies such as the FDA. Consequently, customer retention in the core chromatography business is exceptionally high.
Hardware innovations further reinforce these software-driven switching costs. Waters has successfully engineered solutions that physically enhance analytical sensitivity, such as the MaxPeak Premier technology which mitigates analyte-to-surface interactions during testing. Furthermore, the 2023 acquisition of Wyatt Technology allowed Waters to directly integrate multi-angle light scattering and differential refractive index detection into the Empower ecosystem. By centralizing the data acquisition for large-molecule characterizations within its proprietary software, Waters has effectively locked in biopharmaceutical customers who require rigorous quality control for complex biologic therapeutics.
Industry Dynamics: Opportunities and Threats
The secular transition from traditional small-molecule pharmaceuticals to complex biological therapies represents a massive growth vector for the industry. Cell and gene therapies, mRNA vaccines, and monoclonal antibodies require highly sophisticated structural characterization that legacy analytical instruments simply cannot process. This structural shift forces pharmaceutical companies to continually upgrade their laboratory infrastructure to high-resolution mass spectrometry and advanced bioseparation systems. Furthermore, the convergence of analytical chemistry and clinical diagnostics presents a compelling opportunity. By deploying advanced liquid chromatography-mass spectrometry workflows into clinical settings, laboratories can replace traditional, less precise immunoassays with multiplexed, highly accurate diagnostic tests, driving a new wave of instrument placements in hospitals.
However, the industry is not immune to cyclical macroeconomic pressures. The analytical instrumentation sector remains highly sensitive to capital expenditure budgets. Recent quarters have highlighted structural weaknesses in global academic and government funding, alongside prolonged softness in the Chinese macroeconomic environment. Competitors such as Agilent have openly cited contraction in academic markets and delayed capital deployments as meaningful headwinds. Additionally, the increasing geopolitical friction and the imposition of cross-border tariffs have historically compressed operating margins across the sector. While Waters' shift toward recurring diagnostics revenue mitigates some of this capital equipment volatility, any sustained contraction in global biomedical research and development funding poses a direct threat to organic volume growth.
Innovation Engine and Disruptive Entrants
Continuous product innovation remains central to maintaining pricing power and defending market share. Waters historically allocates between 6 and 7 percent of its total revenue to research and development, a commitment evidenced by a robust vitality index. In mid-2026, the company introduced the Xevo MRT P10 Mass Spectrometer and the Cyclic IMS P20 Mass Spectrometer. These platforms represent significant technological leaps in high-resolution structural and spatial omics. Delivering up to 20 times higher sensitivity and industry-leading acquisition speeds, these systems address the exact bottlenecks researchers face in high-throughput multiomics and biomarker discovery. In the chromatography portfolio, the Alliance iS Bio HPLC System was specifically engineered for biopharmaceutical quality control, utilizing built-in intelligence to eliminate common analytical errors, directly improving laboratory throughput.
The threat of disruptive new entrants in the core hardware space is negligible. The astronomical cost of engineering ultra-precise mass spectrometers, combined with the stringent regulatory demands of pharmaceutical manufacturing, precludes startups from capturing meaningful hardware market share. However, a credible threat is emerging in the software and data interpretation layer. A new cohort of nimble, artificial intelligence-native startups is developing agnostic laboratory data platforms designed to operate across multiple instrument brands. These entities aim to commoditize the hardware layer by shifting the value of data analysis away from legacy chromatography data systems like Empower. While Waters is aggressively integrating machine learning into its own Waters Connect platform to defend its moat, the rapid evolution of cloud-based AI analytics presents an ongoing battle for control over the laboratory informatics ecosystem.
Management Track Record and Execution
Udit Batra assumed the role of Chief Executive Officer in late 2020 during a period of stagnation for Waters. At the time, the company was perceived by the institutional investment community as having lost its commercial momentum and innovative edge to faster-moving peers. Batra executed a clinical turnaround. He systematically overhauled the executive leadership team, decentralized decision-making, and revitalized the core research and development pipeline. The results were evident in accelerated organic growth rates, a restored product vitality index, and a stock performance that significantly outpaced the broader life sciences tools peer group through his initial tenure.
Batra's capital allocation strategy has aggressively repositioned the company's future. Shifting away from a conservative posture, management executed the $1.36 billion acquisition of Wyatt Technology in 2023, astutely capturing a vital component of the large-molecule characterization workflow. However, the true crucible for this management team is the ongoing integration of the $17.5 billion Becton Dickinson biosciences and diagnostics carve-out. Management has committed to delivering $345 million in annualized EBITDA synergies by 2030, alongside significant operating margin expansion. Transitioning Waters from a focused, pure-play analytical instruments manufacturer into a complex, diversified life sciences and diagnostics conglomerate introduces immense execution risk. The long-term credibility of the leadership team will be entirely dictated by their ability to achieve these targeted synergies without alienating the legacy analytical customer base.
The Scorecard
Waters Corporation presents a formidable combination of entrenched market dominance in liquid chromatography and a highly profitable, recurring revenue business model driven by its Empower software ecosystem. The company benefits from immense switching costs in regulated biopharmaceutical testing, providing a structural moat that is difficult for competitors to breach. The recent strategic pivot through the massive acquisition of BD's Biosciences and Diagnostic Solutions fundamentally alters the company's trajectory, drastically expanding its total addressable market while shifting its revenue mix further toward recurring diagnostics and consumables. Management's track record under Udit Batra provides confidence in their operational capability, having previously successfully revitalized the company's core innovation engine.
Conversely, the sheer scale of the BD transaction introduces significant integration risks, bringing execution into sharp focus over the coming years. The analytical instrumentation sector remains highly sensitive to macroeconomic headwinds, particularly within academic and government funding, which have shown recent cyclical weakness. While the core legacy business remains exceptionally robust, the integration of distinct corporate cultures, realization of projected synergies, and the navigation of an increasingly complex regulatory landscape across both analytical tools and clinical diagnostics represent substantial challenges. The ultimate success of Waters will hinge on management's ability to seamlessly synthesize these multi-billion-dollar assets without disrupting the cash-generative core of its chromatography franchise.